PCBL Chemical reported a robust start to FY27, with consolidated net profit after tax (PAT) surging 65% year-on-year to ₹155 crore for the quarter ended June 30, 2026. The growth was underpinned by a 17% increase in revenue from operations to ₹2,474 crore and a 23% rise in EBITDA to ₹400 crore. On July 29, 2026, the Board of Directors approved these unaudited financial results and declared an interim dividend of ₹4.50 per equity share, reflecting strong operational momentum and cash generation capabilities. Shareholders holding shares on the record date of August 4, 2026, will be eligible for the payout, which is scheduled to be paid on or before August 17, 2026.

The Board meeting, held pursuant to Regulations 30, 33, 51, and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, also noted that the statutory auditors, S.R. Batliboi & Co. LLP, issued an unmodified limited review report on the financial statements. In addition to consolidated figures, standalone net profit rose to ₹107 crore from ₹93 crore in the corresponding period last year, while standalone revenue from operations grew to ₹1,658 crore from ₹1,460 crore.

Financial Performance Highlights

PCBL Chemical’s top-line growth was broad-based across its core segments. Consolidated revenue from operations climbed to ₹2,474 crore from ₹2,114 crore in Q1FY26. This expansion contributed to a significant improvement in profitability, with consolidated PAT rising from ₹94 crore to ₹155 crore. The company’s consolidated EBITDA margin expanded to 16% from 15% in the corresponding period last year, indicating improved cost efficiency despite higher input costs. Standalone EBITDA margin also showed strength, supporting the overall group performance.

Segment-Wise Contribution

The Carbon Black segment remained the primary driver of revenue. Domestic carbon black sales volumes grew 15% year-on-year to 102,985 tons, while specialty blacks volume grew 23% year-on-year. Exports volume stood at 50,528 tons. The Specialty & Solutions segment, operated through subsidiary Aquapharm Chemical, reported revenue of ₹394 crore and EBITDA of ₹47 crore. However, total sales volume for Specialty & Solutions declined to 22,985 MT from 25,993 MT in Q1FY26, driven by a sharp drop in Oil & Gas volumes due to geopolitical disruptions and volatile oil prices.

Balance Sheet and Debt Metrics

As of June 30, 2026, PCBL Chemical maintained a consolidated debt-equity ratio of 1.25, slightly up from 1.20 at the end of FY26. The company has an outstanding non-convertible debenture (NCD) amount of ₹490 crore, secured by a pledge over shares of its subsidiary, Aquapharm Chemical Limited. Additionally, the subsidiary Aquapharm Chemical Limited has ₹385 crore in outstanding NCDs, bringing the total consolidated debt to ₹875 crore. The group’s debt service coverage ratio (without prepayment) improved significantly to 2.31 from 1.76 in Q1FY26, demonstrating enhanced ability to meet debt obligations from operating profits. Standalone debt-equity ratio stood at 0.7, down from 0.83 in the previous year.

What the Numbers Show

The divergence between revenue growth (17%) and profit growth (65%) underscores a period of margin expansion for PCBL Chemical. The operating margin improvement suggests that the company successfully passed on higher costs or benefited from favorable product mix dynamics. Furthermore, the declaration of an interim dividend of ₹4.50 per share signals management’s confidence in sustained cash flows and commitment to shareholder returns amidst a strong earnings backdrop.

R K Agarwal ceased to be an Independent Director of pcbl chemical on July 25, 2026, following the completion of his term. The exit marks the end of his contributions to the Board, including his roles in key oversight committees. Consequently, he also stepped down as a member of the Audit Committee and the Sustainability and Risk Management Committee. The Board recorded its appreciation for his service during his tenure. This change ensures compliance with regulatory norms regarding director tenure limits while maintaining committee continuity through immediate reconstitution.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The cessation took effect at the close of business hours on July 25, 2026. The company notified both the National Stock Exchange of India Ltd and BSE Ltd regarding the change in directorship composition.

To maintain the integrity of its oversight structures, the Board approved the induction of Umang Kanoria (DIN: 00081108) as a Member of the Audit Committee, effective July 25, 2026. This appointment followed a recommendation from the Nomination and Remuneration Committee and was formalized via a Circular Resolution passed by the Board of Directors on the same day. Kanoria’s entry ensures that the Audit Committee remains fully constituted and compliant with listing requirements.

The reconstituted Audit Committee now comprises three independent directors. T C Suseel Kumar serves as Chairman, supported by Dr. S Ravi and Umang Kanoria as members. This structure preserves the independence and expertise required for effective financial oversight and risk management within the organization.

Key Changes in Board Composition

Governance Implications

The transition highlights the company’s adherence to statutory timelines for director rotation and committee reconstitution. By appointing Kanoria simultaneously with Agarwal’s exit, the Board avoided any gap in Audit Committee membership, which is critical for ongoing financial reporting and compliance activities. The retention of T C Suseel Kumar as Chairman provides stability during this leadership transition.